



# Maple-Brown Abbott Asian Dividend Growth Fund

Monthly Factsheet – 30 June 2022

## Fund facts

Fund size	\$4 million
Inception date	23 Jun 2021
APIR code	MPL8237AU
Distribution frequency	Semi-annually
Management costs <sup>1</sup>	0.90% p.a.
Minimum investment <sup>1</sup>	\$20,000
Minimum withdrawal <sup>1</sup>	\$1,000
Buy/sell spread <sup>1</sup>	0.28/0.28%
Application price (AUD)	\$0.9991
Redemption price (AUD)	\$0.9935

## Fund snapshot

### Objective

The Fund aims to deliver an attractive total return, after fees, over a five-year period whilst maintaining a dividend yield in excess of the MSCI All Countries Asia excluding Japan Net Index (AUD).

### Features

- High conviction and benchmark unaware – access to a portfolio constructed of the highest conviction opportunities from the investment universe, typically 25–40 stocks, without reference to any underlying benchmark.
- Proprietary screening tools – the Fund uses quantitative screening tools to identify a universe of stocks that meet the strict criteria of having both the ability and intention to maintain and grow dividends.
- Fundamental research – access to the benefits of detailed qualitative analysis conducted on companies which includes detailed financial forecasts, meetings with company management and an assessment of management quality, industry structure and Environmental, Social and Governance (ESG) factors.

### Asset allocation ranges

Asia (ex-Japan) equities	80-100%
Cash	0-20%

### Investment philosophy

Value, active, bottom up

### Portfolio managers

Geoffrey Bazzan and Howard Ho

## Want to find out more?

Contact our Client Service team by:

T 1300 097 995

E [mba@unitregistry.com.au](mailto:mba@unitregistry.com.au)

W [maple-brownabbott.com.au](http://maple-brownabbott.com.au)

## Overview

The Maple-Brown Abbott Asian Dividend Growth Fund (the “Fund”) is an actively managed fund that invests in listed (and to be listed) securities across Asia that we believe have sustainable and growing income streams and the potential for long-term capital growth. We believe one of the key identifiers of strong total returns of Asian equities is dividend growth. The Fund’s investment universe comprises companies across the Asian region with a market capitalisation typically above US\$1 billion dollars. To narrow the investment universe, we apply two distinct quantitative screening models to identify those companies with both the ability to pay a sustainable and attractive dividend stream, and the intention to reward shareholders with an attractive dividend profile going forward. The quantitative screens are complemented by bottom-up fundamental research, where we conduct detailed quantitative and qualitative analysis on select companies that have been identified from the two quantitative screens. This in-depth research includes detailed financial forecasts, meetings with company management and an assessment of management quality, industry structure and ESG factors. The Fund typically holds between 25–40 stocks.

## Performance (%) <sup>2</sup>

	Fund <sup>3</sup>	Reference Benchmark <sup>5</sup>
1 month	-3.4	-0.4
3 months	-0.5	-0.6
1 year	0.0	-18.1
Since inception	0.6	-15.8

## Top 5 holdings (%)

	Weighting
China Mobile	7.3
Nippon Telegraph	5.9
Taiwan Semiconductor Manufact. Co	4.8
Taiwan Secom	4.5
China South Publishing A	3.7

## Dividend yield <sup>4</sup>

	Fund
Fund	5.9
Reference Benchmark <sup>5</sup>	2.9

### Notes:

- 1 Refer to the Fund Product Disclosure Statement (“PDS”) and Additional Information Booklet (“AIB”) for further details.
- 2 Past performance is not a reliable indicator of future performance. Source: Maple-Brown Abbott Ltd, MSCI as at 30 June 2022.
- 3 Fund’s performance is based on the movement in net asset value per unit plus distributions and is before tax and after all fees and charges. Foreign tax credits are not included in the performance figures.
- 4 The dividend yields shown for the Fund are our own forecasts for the 12 month period ending 30 June 2023 of the weighted average dividend yields of the underlying companies held by the Fund as at 30 June 2022. The dividend yields shown for the Reference Benchmark are forecasts for the 12 month period ending 30 June 2023 and are sourced from FactSet. The dividend yields shown for the Fund and the Reference Benchmark do not represent actual results. These figures are estimates only and are based on certain assumptions (including estimated earnings and payout ratios for each of the companies) which may be inaccurate or impacted by unknown risks or unanticipated changes in market conditions. The dividend yields shown above for the Fund and the Reference Benchmark are not guaranteed to occur. Actual outcomes may vary in a materially positive or negative manner.
- 5 Reference Benchmark: MSCI All Countries Asia excluding Japan Net Index (AUD).

# Maple-Brown Abbott Asian Dividend Growth Fund

Monthly Factsheet – 30 June 2022

## Risk measures


	Fund	Reference Benchmark <sup>5</sup>
Daily volatility % p.a. <sup>6</sup>	8.6	10.3
Beta <sup>7</sup>	0.7	

## Annual distributions


Year	Cents per unit	Distribution return %
30 June 2022	2.9277	2.9

For latest Fund commentary [click here](#).

## Fund sector weight (%)



## Fund country weight (%)



## Notes:

<sup>5</sup> Reference Benchmark: MSCI All Countries Asia excluding Japan Net Index (AUD).

<sup>6</sup> Volatility is since inception 23 June 2021. The volatility is calculated for both the Fund and Reference Benchmark. Volatility calculation is annualised and is the standard deviation of daily returns.

<sup>7</sup> Source: UBS

## Disclaimer

This document is prepared and issued by Maple-Brown Abbott Limited ABN 73 001 208 564, AFSL 237296 ("MBA"). It does not constitute advice or a recommendation of any kind and should not be relied upon as such. This document contains general information only, and does not take into account your investment objectives, financial situation or specific needs. Before making any investment decision, you should seek independent investment, legal, tax, accounting or other professional advice as appropriate. This document does not constitute an offer or solicitation by anyone in any jurisdiction. This document is not an advertisement and is not directed at any person in any jurisdiction where the publication or availability of the information is prohibited or restricted by law. Past performance is not a reliable indicator of future performance. An investment in the Fund does not represent an investment in, deposit with or other liability of MBA, and is subject to investment risk including possible delays in repayment and loss of income and principal invested. Neither MBA, nor any of its related parties, directors or employees, make any representation or give any guarantee as to the return of capital, performance, any specific rate of return, or the taxation consequences of, any investment. Any comments about investments are not a recommendation to buy, sell or hold. Any views expressed on individual stocks or other investments, or any forecasts or estimates, are not a recommendation to buy, sell or hold, they are point in time views and may be based on certain assumptions and qualifications not set out in part or in full in this document. Information derived from sources is believed to be accurate, however such information has not been independently verified and may be subject to assumptions and qualifications not described in this document. To the extent permitted by law, neither MBA, nor any of its related parties, directors or employees, make any representation or warranty as to the accuracy, completeness, reasonableness or reliability of this information, or accept liability or responsibility for any losses, whether direct, indirect or consequential, relating to, or arising from, the use or reliance on this information. Units in the Fund are issued by MBA. Before making a decision whether to acquire, or to continue to hold an investment in the Fund, investors should obtain and consider the current PDS, AIB and Target Market Determination (TMD) for the Fund issued by MBA and available at [maple-brownabbott.com.au/document-library](http://maple-brownabbott.com.au/document-library) or by calling 1300 097 995. This information is current as at 30 June 2022 and is subject to change at any time without notice.

MSCI: The MSCI information may only be used for your internal use, may not be reproduced or disseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an "as is" basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the "MSCI Parties") expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages. [(www.msci.com)].

Signatory of:



## Want to find out more?

Contact our Client Service team by:

T 1300 097 995

E [mba@unitregistry.com.au](mailto:mba@unitregistry.com.au)

W [maple-brownabbott.com.au](http://maple-brownabbott.com.au)